Akynzeo Injection
Product Images NDC 69639-106

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Akynzeo (NDC 69639-106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Helsinn Therapeutics (u.s.), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Netupitant Chemical Structure (Akynzeo 1)

FDA Label Image

Ndc 62856-796-04 Akynzeo (netupitant And Palonosetron) Capsules, 300mg/0.5mg (Akynzeo 10)

This is a description of a medication called Akynzeo. It comes in capsule form with a dosage of 300mg/0.5mg per capsule containing netupitant and palonosetron. The manufacturer is Helsinn Birex Pharmaceuticals Ltd in Dublin, Ireland and it is distributed by Helsinn Therapeutics (U), Inc. located in Iselin, NJ. The product is only available by prescription (Rx Only) and the NDC identifier is 69639-101-04.*

FDA Label Image

Ndc 62856-796-04 Akynzeo (netupitant And Palonosetron) Capsules, 300mg/0.5mg (Akynzeo 11)

This text appears to be describing a medication called 'netupitant and palonosetron' which is in capsule form with a strength of 300 mg/0.5 mg per capsule. It also mentions an address, possibly of a manufacturer or distributor, and some other unclear information about buses and numbers.*

FDA Label Image

Akynzeo 12

Akynzeo is a drug that comes in the form of injection vials with a strength of 235mg/0.25mg per vial. It contains fosnetupitant and palonosetron. The drug should be reconstituted and administered through intravenous infusion only. It should be stored in the refrigerator, protected from light and should be used within three hours after reconstitution. Akynzeo is a registered trademark of Helin Heaticare S, Swiss. The drug should not be used with solutions containing DNALENT GATIONS, Ca* M, Non-LUDMA LACIATED RINGER'S SOLUTION, and HARTMANNTS SOLUTION. Noaeo is manufactured by Patheon alls Soh, Maraa, aly.*

FDA Label Image

Akynzeo 13

Akynzeo is a prescription medication that comes in a single-dose vial and is designed for intravenous infusion only. It contains 235mg fosnetupitant and 0.25mg palonosetron and must be reconstituted and diluted. Each vial is stored in the refrigerator, protected from light, and in its carton. The drug is distributed by Helsinn Therapeutics in Iselin, NJ.*

FDA Label Image

Palonosetron Hydrochloride Chemical Structure (Akynzeo 2)

FDA Label Image

Akynzeo 2b

FDA Label Image

Step 1 (Akynzeo 4)

Akynzeo is a medication that comes in a capsule form which contains 300mg of netupitant and 0.5mg of palonosetron. Additional information is not available from the given text.*

FDA Label Image

Step 2 (Akynzeo 5)

FDA Label Image

Step 3 (Akynzeo 6)

FDA Label Image

Step 4 (Akynzeo 7)

FDA Label Image

Ndc 62856-796-01 Akynzeo (netupitant And Palonosetron) Capsules, 300mg/0.5mg (Akynzeo 8)

FDA Label Image

Ndc 62856-796-01 Akynzeo (netupitant And Palonosetron) Capsules, 300mg/0.5mg (Akynzeo 9)

FDA Label Image

Akynzeo Fig

FDA Label Image

Carton Inj

Akynzeo is a drug available in injection form. It contains two active ingredients: fosnetupitant and palonosetron. The injection is available in a single-dose vial containing 235 mg/0.25 mg per 20 ml. Akynzeo is manufactured by Baxter Oncology GmbH in Germany and is a registered trademark of Kelsinn Kealtcare SA, used under license. The drug should be diluted as per the instructions found in the accompanying directions for use. The final solution should be used within 26 hours and stored at room temperature. The injection solution contains Fosnetupitant and Palonosetron and is to be diluted with either 5% dextrose injection or 0.9% sodium chloride injection. Not available for use with solutions containing divalent cations.*

FDA Label Image

Vial Inj

Akynzeo is a prescription medication that comes in a single-dose vial and contains fosnetupitant and palonosetron. It must be diluted and administered through intravenous infusion. Each vial contains 235mg of Fosmeluptanl and 0.25mg of Palonosetron, equivalent to 260 mg fosnetupitant chloride hydrochloride and 0.28 mg palonosstron hydrochloride, respectively. It should be stored in a box, protected from light and at temperature ranging from 20°C-25°C (68°F-77°F). It is distributed by Helsinn Therapeutics (U.S.), Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.